Nasdaq · Healthcare
PHIBRO ANIMAL HEALTH CORP (PAHC)
As-reported financials and recent SEC filings for PHIBRO ANIMAL HEALTH CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.30B
Net income
$48.3M
Net margin
3.7%
Diluted EPS
$1.19
ROE
16.9%
P/E (TTM)
13.6×
Market cap
$1.29B
Debt / equity
2.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.30B | $1.02B | $977.9M | $942.3M | $833.4M |
| Gross profit | $399.9M | $313.1M | $298.2M | $285.4M | $271.4M |
| Operating income | $110.5M | $53.3M | $71.8M | $79.0M | $74.9M |
| Net income | $48.3M | $2.4M | $32.6M | $49.2M | $54.4M |
| Diluted EPS | $1.19 | $0.06 | $0.81 | $1.21 | $1.34 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-26
View on EDGAR →1442026-06-16
View on EDGAR →42026-06-02
View on EDGAR →SCHEDULE 13D/A2026-05-22
View on EDGAR →SCHEDULE 13G/A2026-05-14
View on EDGAR →42026-05-07
View on EDGAR →8-K2026-05-06
View on EDGAR →10-Q2026-05-06
View on EDGAR →Go deeper on PAHC
Search PHIBRO ANIMAL HEALTH CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.